Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1980 Dec;18(6):933–938. doi: 10.1128/aac.18.6.933

Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction.

W K Bolton, W M Scheld, D A Spyker, T L Overby, M A Sande
PMCID: PMC352992  PMID: 6453555

Abstract

We have examined the pharmacokinetics of moxalactam (LY127935) in 36 subjects with various degrees of renal dysfunction. Creatinine clearance (Ccr)/1.73 m2 ranged from zero to 135.8 ml/min. After a 1-g administration of moxalactam intravenously, the volume of distribution was 20.6 /+- 9.5 liters (0.28 liter/kg), and the mean half-life ranged from 3.1 h for subjects with Ccr greater than 65 ml/min to 19.3 h for subjects with Ccr less than 10 ml/min. The moxalactam clearance was closely correlated to Ccr (r = 0.93, P less than 0.0001) and excretion of antibiotic was 73.6 +/- 13% in normal subjects. Renal clearance accounted for 90% of moxalactam clearance in the normal subjects. A dosage schedule for administering moxalactam to patients with various degrees of renal dysfunction is provided.

Full text

PDF
933

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barza M., Tally F. P., Jacobus N. V., Gorbach S. L. In vitro activity of LY127935. Antimicrob Agents Chemother. 1979 Sep;16(3):287–292. doi: 10.1128/aac.16.3.287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brogard J. M., Pinget M., Brandt C., Lavillaureix J. Pharmacokinetics of cefazolin in patients with renal failure; special reference to hemodialysis. J Clin Pharmacol. 1977 Apr;17(4):225–230. doi: 10.1177/009127007701700406. [DOI] [PubMed] [Google Scholar]
  3. Craig W. A., Welling P. G., Jackson T. C., Kunin C. M. Pharmacology of cefazolin and other cephalosporins in patients with renal insufficiency. J Infect Dis. 1973 Oct;128(Suppl):S347–S345. doi: 10.1093/infdis/128.supplement_2.s347. [DOI] [PubMed] [Google Scholar]
  4. Fass R. J. In vitro activity of LY127935. Antimicrob Agents Chemother. 1979 Oct;16(4):503–509. doi: 10.1128/aac.16.4.503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Flournoy D. J., Perryman F. A. LY127935, a new beta-lactam antibiotic, versus Proteus, Klebsiella, Serratia, and Pseudomonas. Antimicrob Agents Chemother. 1979 Nov;16(5):641–643. doi: 10.1128/aac.16.5.641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Forbes G. B. Stature and lean body mass. Am J Clin Nutr. 1974 Jun;27(6):595–602. doi: 10.1093/ajcn/27.6.595. [DOI] [PubMed] [Google Scholar]
  7. Gentamicin dosage. Ann Intern Med. 1977 Mar;86(3):357–359. doi: 10.7326/0003-4819-86-3-357. [DOI] [PubMed] [Google Scholar]
  8. Kirby W. M., Regamey C. Pharmacokinetics of cefazolin compared with four other cephalosporins. J Infect Dis. 1973 Oct;128(Suppl):S341–S346. doi: 10.1093/infdis/128.supplement_2.s341. [DOI] [PubMed] [Google Scholar]
  9. Levison M. E., Levison S. P., Ries K., Kaye D. Pharmacology of cefazolin in patients with normal and abnormal renal function. J Infect Dis. 1973 Oct;128(Suppl):S354–S357. doi: 10.1093/infdis/128.supplement_2.s354. [DOI] [PubMed] [Google Scholar]
  10. Neu H. C., Aswapokee N., Fu K. P., Aswapokee P. Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds. Antimicrob Agents Chemother. 1979 Aug;16(2):141–149. doi: 10.1128/aac.16.2.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Schrogie J. J., Rogers J. D., Yeh K. C., Davies R. O., Holmes G. I., Skeggs H., Martin C. M. Pharmacokinetics and comparative pharmacology of cefoxitin and cephalosporins. Rev Infect Dis. 1979 Jan-Feb;1(1):90–98. doi: 10.1093/clinids/1.1.90. [DOI] [PubMed] [Google Scholar]
  12. Spyker D. A., Rugloski R. J., Vann R. L., O'Brien W. M. Pharmacokinetics of amoxicillin: dose dependence after intravenous, oral, and intramuscular administration. Antimicrob Agents Chemother. 1977 Jan;11(1):132–141. doi: 10.1128/aac.11.1.132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Spyker D. A., Spyker J. M. Response model analysis for cross-fostering studies: prenatal versus postnatal effects on offspring exposed to methylmercury dicyandiamide. Toxicol Appl Pharmacol. 1977 Jun;40(3):511–527. doi: 10.1016/0041-008x(77)90077-1. [DOI] [PubMed] [Google Scholar]
  14. Spyker D. A., Thomas B. L., Sande M. A., Bolton W. K. Pharmacokinetics of cefaclor and cephalexin: dosage nomograms for impaired renal function. Antimicrob Agents Chemother. 1978 Aug;14(2):172–177. doi: 10.1128/aac.14.2.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Trager G. M., White G. W., Zimelis V. M., Panwalker A. P. LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity. Antimicrob Agents Chemother. 1979 Sep;16(3):297–300. doi: 10.1128/aac.16.3.297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Wise R., Andrews J. M., Bedford K. A. LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics. Antimicrob Agents Chemother. 1979 Sep;16(3):341–345. doi: 10.1128/aac.16.3.341. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES